Stephens Investment Management Group LLC Grows Stake in Insulet Corporation $PODD

Key Points

• Stephens Investment Management Group LLC increased its stake in Insulet Corporation by 11.8% during the second quarter, owning 133,852 shares valued at approximately $42 million.
• Insulet reported a $1.17 earnings per share for the last quarter, exceeding the expected $0.92, along with revenue of $649.1 million, reflecting a 32.9% year-over-year increase.
• Analysts have raised their price targets for Insulet, with Oppenheimer and Royal Bank of Canada both setting targets of $365, while JPMorgan Chase increased theirs to $415.

Stephens Investment Management Group LLC increased its holdings in shares of Insulet Corporation (NASDAQ:PODD - Free Report) by 11.8% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 133,852 shares of the medical instruments supplier's stock after acquiring an additional 14,120 shares during the quarter. Stephens Investment Management Group LLC owned about 0.19% of Insulet worth $42,054,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Larson Financial Group LLC boosted its position in Insulet by 426.3% during the first quarter. Larson Financial Group LLC now owns 100 shares of the medical instruments supplier's stock worth $26,000 after acquiring an additional 81 shares during the last quarter. Zions Bancorporation National Association UT acquired a new position in Insulet during the first quarter worth about $26,000. SouthState Corp boosted its position in Insulet by 253.3% during the first quarter. SouthState Corp now owns 106 shares of the medical instruments supplier's stock worth $28,000 after acquiring an additional 76 shares during the last quarter. Kozak & Associates Inc. acquired a new position in Insulet during the second quarter worth about $32,000. Finally, Trust Co. of Toledo NA OH acquired a new position in Insulet during the second quarter worth about $35,000.

Insulet Price Performance

Insulet stock opened at $328.97 on Wednesday. Insulet Corporation has a 1 year low of $226.50 and a 1 year high of $353.50. The company's 50 day simple moving average is $327.04 and its 200-day simple moving average is $303.28. The company has a market capitalization of $23.16 billion, a price-to-earnings ratio of 99.99, a price-to-earnings-growth ratio of 2.73 and a beta of 1.40. The company has a debt-to-equity ratio of 0.64, a quick ratio of 1.81 and a current ratio of 2.26.

Insulet (NASDAQ:PODD - Get Free Report) last announced its earnings results on Thursday, August 7th. The medical instruments supplier reported $1.17 earnings per share for the quarter, topping the consensus estimate of $0.92 by $0.25. Insulet had a net margin of 10.01% and a return on equity of 23.78%. The firm had revenue of $649.10 million for the quarter, compared to the consensus estimate of $612.31 million. During the same period in the prior year, the firm earned $0.55 EPS. The firm's revenue for the quarter was up 32.9% on a year-over-year basis. Insulet has set its FY 2025 guidance at EPS. Q3 2025 guidance at EPS. As a group, equities research analysts expect that Insulet Corporation will post 3.92 earnings per share for the current year.

Insider Activity at Insulet

In other Insulet news, SVP Prem Singh sold 687 shares of the business's stock in a transaction that occurred on Monday, September 8th. The shares were sold at an average price of $347.49, for a total transaction of $238,725.63. Following the completion of the transaction, the senior vice president owned 3,456 shares in the company, valued at $1,200,925.44. The trade was a 16.58% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, SVP Laetitia Cousin sold 797 shares of the business's stock in a transaction that occurred on Monday, September 8th. The stock was sold at an average price of $348.81, for a total transaction of $278,001.57. Following the transaction, the senior vice president owned 3,890 shares of the company's stock, valued at $1,356,870.90. This trade represents a 17.00% decrease in their position. The disclosure for this sale can be found here. 0.39% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

A number of equities analysts recently weighed in on PODD shares. Oppenheimer boosted their price target on shares of Insulet from $324.00 to $365.00 and gave the stock an "outperform" rating in a research report on Monday, September 8th. Royal Bank Of Canada boosted their target price on shares of Insulet from $350.00 to $365.00 and gave the company an "outperform" rating in a report on Friday, October 10th. JPMorgan Chase & Co. boosted their target price on shares of Insulet from $340.00 to $415.00 and gave the company an "overweight" rating in a report on Friday, September 12th. Jefferies Financial Group reiterated a "buy" rating on shares of Insulet in a report on Thursday, August 7th. Finally, Zacks Research upgraded shares of Insulet from a "hold" rating to a "strong-buy" rating in a report on Tuesday, October 14th. One analyst has rated the stock with a Strong Buy rating, nineteen have given a Buy rating and two have assigned a Hold rating to the company's stock. According to data from MarketBeat, the company has an average rating of "Moderate Buy" and an average price target of $352.11.

Insulet Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.